ConforMIS Inc. (NASDAQ:CFMS) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the stock. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $14.33.

Several brokerages have commented on CFMS. B. Riley began coverage on shares of ConforMIS in a research report on Wednesday, September 21st. They issued a “buy” rating and a $13.00 price objective on the stock. SunTrust Banks Inc. began coverage on shares of ConforMIS in a research report on Monday, September 19th. They issued a “buy” rating and a $14.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on shares of ConforMIS from $11.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 9th. Oppenheimer Holdings Inc. lifted their price objective on shares of ConforMIS from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 9th. Finally, Zacks Investment Research raised shares of ConforMIS from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th.

ConforMIS (NASDAQ:CFMS) opened at 10.29 on Friday. ConforMIS has a 52 week low of $4.80 and a 52 week high of $23.62. The company’s market cap is $433.49 million. The company has a 50-day moving average of $8.91 and a 200 day moving average of $8.82.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.01. The business had revenue of $19.30 million for the quarter, compared to analyst estimates of $18.02 million. ConforMIS had a negative net margin of 84.33% and a negative return on equity of 45.30%. The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.51) earnings per share. On average, equities analysts forecast that ConforMIS will post ($1.40) EPS for the current fiscal year.

In related news, Director Kenneth P. Fallon III sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $8.44, for a total transaction of $33,760.00. Following the completion of the transaction, the director now owns 92,222 shares of the company’s stock, valued at $778,353.68. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Philipp Lang sold 10,410 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $10.03, for a total transaction of $104,412.30. Following the transaction, the chief executive officer now directly owns 483,378 shares of the company’s stock, valued at approximately $4,848,281.34. The disclosure for this sale can be found here. Corporate insiders own 9.20% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Cowen Group Inc. purchased a new position in shares of ConforMIS during the second quarter valued at approximately $445,000. Schwab Charles Investment Management Inc. boosted its position in shares of ConforMIS by 308.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 56,000 shares of the company’s stock valued at $394,000 after buying an additional 42,300 shares in the last quarter. Redmile Group LLC boosted its position in shares of ConforMIS by 32.2% in the second quarter. Redmile Group LLC now owns 1,047,821 shares of the company’s stock valued at $7,356,000 after buying an additional 255,466 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new position in shares of ConforMIS during the second quarter valued at approximately $204,000. Finally, State Street Corp boosted its position in shares of ConforMIS by 238.4% in the second quarter. State Street Corp now owns 458,834 shares of the company’s stock valued at $3,221,000 after buying an additional 323,234 shares in the last quarter. 41.13% of the stock is owned by institutional investors.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee.

5 Day Chart for NASDAQ:CFMS

Receive News & Stock Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related stocks with our FREE daily email newsletter.